Quarterly Financial Results for Period Ended June 27, 2026 - Contains consolidated financial statements including balance sheet, income statement, and cash flow statement comparing Q2 2026 performance to prior year periods (Q2 2025 and year-to-date comparisons through June 28, 2025) Product and Service Revenue Breakdown - Reports revenue segmented by product and service categories for the…

Our analysis rates this filing NEUTRAL. Thermo Fisher Scientific presents a balanced risk profile appropriate for a large-cap, investment-grade industrial company. The identified concerns—debt maturity scheduling and extended warranty obligations—are routine operational matters rather than material…

Concern level: ELEVATED (4.2/10). Key factors: Debt maturity concentration in 2026-2027 requiring refinancing ($3.2B due 2026, $1.45B and $1.75B due 2027); Refinancing risk exposure if credit markets tighten or company performance deteriorates; Extended warranty and service agreement obligations create 3-year performance contingencies.

Notable risk changes: No material negative events or risk escalations identified in Q2 2026 10-Q filing; Debt structure shows normal maturity ladder with no covenant violations or liquidity concerns disclosed; Filing contains standard XBRL financial data with no restatements, impairments, or accounting adjustments flagged.

The model predicts TMO will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.